Welcome to our dedicated page for TILRAY BRANDS news (Ticker: TLRY), a resource for investors and traders seeking the latest updates and insights on TILRAY BRANDS stock.
Tilray Brands Inc. (TLRY) maintains a dynamic presence in global cannabis markets through its medical research initiatives and consumer product innovations. This resource provides investors and industry observers with centralized access to verified corporate announcements, regulatory developments, and market analysis.
Users will find updates spanning earnings reports, international expansion efforts, and product portfolio enhancements, including developments in cannabis-infused wellness solutions. The curated selection enables stakeholders to track operational milestones across Tilray's pharmaceutical-grade production facilities and lifestyle brand divisions.
All content undergoes strict verification to ensure alignment with financial disclosure standards and industry regulations. Regular updates reflect Tilray's position as a GMP-certified producer serving medical markets in 20+ countries while expanding recreational offerings in emerging markets.
Bookmark this page for streamlined monitoring of Tilray's strategic initiatives, quality control advancements, and responses to evolving cannabis legislation worldwide.
Tilray, a prominent cannabis-lifestyle company, has launched Symbios, a new medical brand in Canada, designed to enhance its product offerings. Symbios aims to provide a diverse range of formats and cannabinoid ratios at competitive prices, catering to medical patients’ health needs. Alongside this, Tilray introduced high-potency medical cannabis topicals under the Aphria brand targeting inflammatory joint diseases. CEO Irwin D. Simon emphasized innovation and patient care as key components of Tilray's global growth strategy, aiming to build on momentum across its medical brands.
Tilray (NASDAQ: TLRY) announced participation in two investor conferences in June 2021. The first is the Jefferies Virtual Healthcare Conference on June 1 at 8:30 AM ET, followed by the Stifel Cross Sector Insight Conference on June 8 at 4:00 PM ET. Webcast details will be available on the company’s website under the Investors section. Tilray is a pioneering global cannabis and consumer packaged goods company dedicated to enhancing well-being through high-quality products across various markets, including Canada, the US, Europe, and beyond.
Tilray announced its participation in the BMO Capital Markets 16th Annual Farm to Market Conference on May 19, 2021, with a presentation scheduled for 8:40 AM ET. Investors can access the conference details and webcast information through the Tilray website.
Tilray is a leading global cannabis-lifestyle company with operations in multiple regions, committed to enhancing well-being through high-quality products and innovative brands. The company aims to be a trusted partner for consumers, offering over 20 brands across more than 20 countries.
Tilray announced that its class 2 common stock (TLRY) began trading on the Toronto Stock Exchange as of May 5, 2021, while continuing to be listed on the Nasdaq. Following the merger with Aphria, shareholders of Aphria received 0.8381 Tilray Shares for each Aphria Share held as of April 30, 2021. Tilray aims to enhance well-being through its diverse portfolio of over 20 brands across various sectors, including cannabis, hemp, and alcoholic beverages, establishing itself as a leader in the global cannabis market.
Tilray and Aphria have successfully completed their business combination, forming the largest global cannabis-focused consumer packaged goods company with a market cap of about US$8.2 billion. Tilray Shares will trade on Nasdaq and the Toronto Stock Exchange under the ticker symbol 'TLRY'. Each Aphria shareholder received 0.8381 Tilray Shares for every Aphria share held. The company aims to leverage its operational scale, enhanced consumer presence, and substantial cost synergies of approximately US$81 million within 18 months, focusing on global growth and profitability.
Tilray, Inc. (NASDAQ: TLRY) announced a bylaw amendment reducing the quorum requirement for shareholder meetings from a majority to one-third of voting power. This change is in connection with the proposed merger with Aphria Inc., allowing for shareholder votes at the upcoming special meeting on April 30. Tilray encourages all stockholders to participate in voting, regardless of share numbers. Proxies already submitted will be counted unless revoked. Tilray operates globally in cannabis research, cultivation, and distribution, serving thousands of customers across 17 countries.
Tilray (NASDAQ: TLRY) announced the adjournment of its special stockholder meeting, originally set for April 16, 2021, to April 30, 2021, to allow more time for stockholders to vote on the business combination with Aphria Inc. Stockholders who have already voted do not need to recast their votes. The meeting will be held via live webcast, and all stockholders are urged to participate. The transaction aims to strengthen Tilray’s market position in the cannabis industry and enhance shareholder value.
Aphria and Tilray are set to hold special meetings on April 14 and April 16, 2021, to approve their proposed business combination. Aphria has received necessary regulatory approvals and an interim order from the Ontario Superior Court for the arrangement. The combined entity will become the world's largest cannabis company, projecting pro forma revenue of US$685 million. Both Boards recommend their shareholders vote ‘FOR’ the transaction. Expected cost synergies of US$78 million will enhance operational efficiency, while the combined company aims for growth in domestic and international markets.
